NewAmsterdam Pharma (NAMS) Other financing activities (2024 - 2025)
NewAmsterdam Pharma's (NAMS) quarterly Other financing activities came in at $1.6 million in Q1 2025, up 207.96% year-on-year from $515000.0 in Q1 2024, and up 207.96% quarter-over-quarter from $515000.0 in Q1 2024.
NewAmsterdam Pharma (NAMS) Other financing activities (2024 - 2025) Analysis & Trends
NewAmsterdam Pharma has disclosed Other financing activities across 2 years of filings, most recently posting $1.6 million for Q1 2025.
- Other financing activities for Q1 2025 came in at $1.6 million, up 207.96% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.6 million (up 207.96% YoY), and the FY2025 annual result was $1.6 million, up 207.96% from the prior year.
- Other financing activities came in at $1.6 million for Q1 2025 at NewAmsterdam Pharma, up from $515000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $1.6 million in Q1 2025 to a low of $515000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | NewAmsterdam Pharma | 3.63 Bn | 3.63 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.59 Mn |
| Mar 31, 2025 | 1.59 Mn |
| Mar 31, 2024 | 515,000.00 |
| Mar 31, 2024 | 515,000.00 |